These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

906 related articles for article (PubMed ID: 24674295)

  • 1. Gestational trophoblastic neoplasia after achieving a nondetectable serum human chorionic gonadotrophin level.
    Gueye M; Kane-Gueye SM; Ndiaye-Gueye MD; Mbaye M; Diouf AA; Niang MM; Diallo M; Moreau JC
    BJOG; 2014 Oct; 121(11):1415-9. PubMed ID: 24674295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gestational trophoblastic neoplasia after spontaneous human chorionic gonadotropin normalization following molar pregnancy evacuation.
    Braga A; Maestá I; Matos M; Elias KM; Rizzo J; Viggiano MG
    Gynecol Oncol; 2015 Nov; 139(2):283-7. PubMed ID: 26383828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of gestational trophoblastic neoplasia after hCG normalisation according to hydatidiform mole type.
    Schmitt C; Doret M; Massardier J; Hajri T; Schott AM; Raudrant D; Golfier F
    Gynecol Oncol; 2013 Jul; 130(1):86-9. PubMed ID: 23523617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does a human chorionic gonadotropin level of over 20,000 IU/L four weeks after uterine evacuation for complete hydatidiform mole constitute an indication for chemotherapy for gestational trophoblastic neoplasia?
    Braga A; Biscaro A; do Amaral Giordani JM; Viggiano M; Elias KM; Berkowitz RS; Seckl MJ
    Eur J Obstet Gynecol Reprod Biol; 2018 Apr; 223():50-55. PubMed ID: 29477553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hormonal contraceptive use before hCG remission does not increase the risk of gestational trophoblastic neoplasia following complete hydatidiform mole: a historical database review.
    Braga A; Maestá I; Short D; Savage P; Harvey R; Seckl MJ
    BJOG; 2016 Jul; 123(8):1330-5. PubMed ID: 26444183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Analysis of prophylactic chemotherapy outcome and clinical characteristics in patients of high-risk hydatidiform mole].
    Geng S; Feng FZ; Xiang Y; Wan XR; Zhou Y
    Zhonghua Fu Chan Ke Za Zhi; 2011 Jan; 46(1):24-7. PubMed ID: 21429430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human chorionic gonadotrophin regression rate as a predictive factor of postmolar gestational trophoblastic neoplasm in high-risk hydatidiform mole: a case-control study.
    Kim BW; Cho H; Kim H; Nam EJ; Kim SW; Kim S; Kim YT; Kim JH
    Eur J Obstet Gynecol Reprod Biol; 2012 Jan; 160(1):100-5. PubMed ID: 22055909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Combination chemotherapy with etoposide and cisplatin for high-risk, chemorefractory and recurrent gestational trophoblastic neoplasia].
    Jiang J; Nan FF; Yang XS; Zhang YZ; Wang B; Kong BH
    Zhonghua Fu Chan Ke Za Zhi; 2007 Sep; 42(9):595-9. PubMed ID: 17983513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postevacuation hCG levels and risk of gestational trophoblastic neoplasia in women with complete molar pregnancy.
    Wolfberg AJ; Berkowitz RS; Goldstein DP; Feltmate C; Lieberman E
    Obstet Gynecol; 2005 Sep; 106(3):548-52. PubMed ID: 16135585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What is the optimal duration of human chorionic gonadotrophin surveillance following evacuation of a molar pregnancy? A retrospective analysis on over 20,000 consecutive patients.
    Coyle C; Short D; Jackson L; Sebire NJ; Kaur B; Harvey R; Savage PM; Seckl MJ
    Gynecol Oncol; 2018 Feb; 148(2):254-257. PubMed ID: 29229282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Therapeutic evaluation of cisplatin, etoposide, and bleomycin chemotherapy regimen in high-risk gestational trophoblastic neoplasia].
    Song SQ; Zhang GN
    Zhonghua Fu Chan Ke Za Zhi; 2012 Aug; 47(8):571-6. PubMed ID: 23141175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Do we need post-pregnancy screening with human chorionic gonadotrophin after previous hydatidiform mole to identify patients with recurrent gestational trophoblastic disease?
    Earp KE; Hancock BW; Short D; Harvey RA; Fisher RA; Drew D; Sarwar N; Tidy JA; Winter MC; Chien P; Seckl MJ
    Eur J Obstet Gynecol Reprod Biol; 2019 Mar; 234():117-119. PubMed ID: 30684876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does hormonal contraception during molar pregnancy follow-up influence the risk and clinical aggressiveness of gestational trophoblastic neoplasia after controlling for risk factors?
    Dantas PRS; Maestá I; Filho JR; Junior JA; Elias KM; Howoritz N; Braga A; Berkowitz RS
    Gynecol Oncol; 2017 Nov; 147(2):364-370. PubMed ID: 28927899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fatal cases of gestational trophoblastic neoplasia over four decades in the Netherlands: a retrospective cohort study.
    Lybol C; Centen DW; Thomas CM; ten Kate-Booij MJ; Verheijen RH; Sweep FC; Ottevanger PB; Massuger LF
    BJOG; 2012 Nov; 119(12):1465-72. PubMed ID: 22925191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of persistent gestational trophobalstic neoplasia: the role of hCG level and ratio in 2 weeks after evacuation of complete mole.
    Kang WD; Choi HS; Kim SM
    Gynecol Oncol; 2012 Feb; 124(2):250-3. PubMed ID: 22094931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Late spontaneous resolution of persistent molar pregnancy.
    Taylor F; Short D; Harvey R; Winter MC; Tidy J; Hancock BW; Savage PM; Sarwar N; Seckl MJ; Coleman RE
    BJOG; 2016 Jun; 123(7):1175-81. PubMed ID: 26774079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subsequent pregnancy outcomes after complete and partial molar pregnancy, recurrent molar pregnancy, and gestational trophoblastic neoplasia: an update from the New England Trophoblastic Disease Center.
    Vargas R; Barroilhet LM; Esselen K; Diver E; Bernstein M; Goldstein DP; Berkowitz RS
    J Reprod Med; 2014; 59(5-6):188-94. PubMed ID: 24937955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low risk of relapse after achieving undetectable HCG levels in women with complete molar pregnancy.
    Wolfberg AJ; Feltmate C; Goldstein DP; Berkowitz RS; Lieberman E
    Obstet Gynecol; 2004 Sep; 104(3):551-4. PubMed ID: 15339768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple pregnancy with complete hydatidiform mole and coexisting normal fetus in a retrospective cohort of 141 patients.
    Hajri T; Massoud M; Vergne M; Descargues P; Allias F; You B; Lotz JP; Haesebaert J; Bolze PA; Golfier F; Massardier J
    Am J Obstet Gynecol; 2024 Mar; 230(3):362.e1-362.e8. PubMed ID: 37722570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The risk of post-molar gestational trophoblastic neoplasia is higher in heterozygous than in homozygous complete hydatidiform moles.
    Baasanjav B; Usui H; Kihara M; Kaku H; Nakada E; Tate S; Mitsuhashi A; Matsui H; Shozu M
    Hum Reprod; 2010 May; 25(5):1183-91. PubMed ID: 20208060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.